Documenti analoghi

• A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers
  di: Yanina Hiriart, et al.
  Pubblicazione: (2024)
• Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
  di: Kexu Yang, et al.
  Pubblicazione: (2026)
• Safety, tolerability, pharmacokinetics and pharmacodynamics of HSK31858, a novel oral dipeptidyl peptidase‐1 inhibitor, in healthy volunteers: An integrated phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose study
  di: Yuhao Wang, et al.
  Pubblicazione: (2025)
• Pharmacokinetics, safety, tolerability and fluorescence imaging of nizaracianine triflutate administered in three divided doses to healthy volunteers
  di: Lisanne K. A. Neijenhuis, et al.
  Pubblicazione: (2026)
• Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial
  di: Alexander Hincker, et al.
  Pubblicazione: (2024)